1
|
Naimy S, Sølberg JBK, Kuczek DE, Løvendorf MB, Bzorek M, Litman T, Mund A, Rahbek Gjerdrum LM, Clark RA, Mann M, Dyring-Andersen B. Comparative Quantitative Proteomic Analysis of Melanoma Subtypes, Nevus-Associated Melanoma, and Corresponding Nevi. J Invest Dermatol 2024; 144:1608-1621.e4. [PMID: 38185415 DOI: 10.1016/j.jid.2023.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 12/01/2023] [Accepted: 12/04/2023] [Indexed: 01/09/2024]
Abstract
A substantial part of cutaneous malignant melanomas develops from benign nevi. However, the precise molecular events driving the transformation from benign to malignant melanoma are not well-understood. We used laser microdissection and mass spectrometry to analyze the proteomes of melanoma subtypes, including superficial spreading melanomas (n = 17), nodular melanomas (n = 17), and acral melanomas (n = 15). Furthermore, we compared the proteomes of nevi cells with those of melanoma cells within the same specimens (nevus-associated melanoma (n = 14)). In total, we quantified 7935 proteins. Despite the genomic and clinical differences of the melanoma subtypes, our analysis revealed relatively similar proteomes, except for the upregulation of proteins involved in immune activation in nodular melanomas versus acral melanomas. Examining nevus-associated melanoma versus nevi, we found 1725 differentially expressed proteins (false discovery rate < 0.05). Among these proteins were 140 that overlapped with cancer hallmarks, tumor suppressors, and regulators of metabolism and cell cycle. Pathway analysis indicated aberrant activation of the phosphoinositide 3-kinase-protein kinase B-mTOR pathways and the Hippo-YAP pathway. Using a classifier, we identified six proteins capable of distinguishing melanoma from nevi samples. Our study represents a comprehensive comparative analysis of the proteome in melanoma subtypes and associated nevi, offering insights into the biological behavior of these distinct entities.
Collapse
Affiliation(s)
- Soraya Naimy
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Pathology, Zealand University Hospital, Roskilde, Denmark
| | - Julie B K Sølberg
- Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Copenhagen, Denmark
| | - Dorota E Kuczek
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Marianne Bengtson Løvendorf
- Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Copenhagen, Denmark; Leo Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Michael Bzorek
- Department of Pathology, Zealand University Hospital, Roskilde, Denmark
| | - Thomas Litman
- Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Andreas Mund
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Rachael A Clark
- Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Matthias Mann
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Beatrice Dyring-Andersen
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Copenhagen, Denmark; Leo Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
2
|
Xie F, Qu J, Lin D, Feng K, Tan M, Liao H, Zeng L, Xiong Q, Huang J, Chen W. Reduced Proteolipid Protein 2 promotes endoplasmic reticulum stress-related apoptosis and increases drug sensitivity in acute myeloid leukemia. Mol Biol Rep 2023; 51:10. [PMID: 38085372 DOI: 10.1007/s11033-023-08994-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 10/30/2023] [Indexed: 12/18/2023]
Abstract
BACKGROUND The Proteolipid Protein 2 (PLP2), a protein in the Endoplasmic Reticulum (ER) membrane, has been reported to be highly expressed in various tumors. Previous studies have demonstrated that the reduced PLP2 can induce apoptosis and autophagy through ER stress-related pathways, leading to a decreased proliferation and aggressiveness. However, there is no research literature on the role of PLP2 in Acute Myeloid Leukemia (AML). METHODS PLP2 expression, clinical data, genetic mutations, and karyotype changes from GEO, TCGA, and timer2.0 databases were analyzed through the R packages. The possible functions and pathways of cells were explored through GO, KEGG, and GSEA enrichment analysis using the clusterProfiler R package. Immuno-infiltration analysis was conducted using the Cibersort algorithm and the Xcell R package. RT-PCR and western blot techniques were employed to identify the PLP2 expression, examine the knockdown effects in THP-1 cells, and assess the expression of genes associated with endoplasmic reticulum stress and apoptosis. Flow cytometry was utilized to determine the apoptosis and survival rates of different groups. RESULTS PLP2 expression was observed in different subsets of AML and other cancers. Enrichment analyses revealed that PLP2 was involved in various tumor-related biological processes, primarily apoptosis and lysosomal functions. Additionally, PLP2 expression showed a strong association with immune cell infiltration, particularly monocytes. In vitro, the knockdown of PLP2 enhanced endoplasmic reticulum stress-related apoptosis and increased drug sensitivity in THP-1 cells. CONCLUSIONS PLP2 could be a novel therapeutic target in AML, in addition, PLP2 is a potential endoplasmic reticulum stress regulatory gene in AML.
Collapse
Affiliation(s)
- Fahui Xie
- Department of Clinical Laboratory, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Jia Qu
- Department of Hematology, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Dainan Lin
- Department of Hematology, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Kexin Feng
- Department of Hematology, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Mingzhu Tan
- Department of Hematology, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Haixiu Liao
- Department of Clinical Laboratory, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Longhui Zeng
- Department of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Qingquan Xiong
- Department of Basic Medical Science, Sino-French Hoffmann Institute, Guangzhou Medical University, Guangzhou, China
| | - Jun Huang
- Department of Basic Medical Science, Sino-French Hoffmann Institute, Guangzhou Medical University, Guangzhou, China.
| | - Weiwen Chen
- Department of Clinical Laboratory, Guangzhou Twelfth People's Hospital, Guangzhou Medical University, Guangzhou, China.
| |
Collapse
|
3
|
Maia VSC, Berzaghi R, Arruda DC, Machado FC, Loureiro LL, Melo PMS, Morais AS, Budu A, Travassos LR. PLP2-derived peptide Rb4 triggers PARP-1-mediated necrotic death in murine melanoma cells. Sci Rep 2022; 12:2890. [PMID: 35190586 PMCID: PMC8861012 DOI: 10.1038/s41598-022-06429-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 01/12/2022] [Indexed: 12/28/2022] Open
Abstract
Malignant melanoma is the main cause of death in patients with skin cancer. Overexpression of Proteolipid protein 2 (PLP2) increased tumor metastasis and the knockdown of PLP2 inhibited the growth and metastasis of melanoma cells. In the present work, we studied the antitumor activity of peptide Rb4 derived from protein PLP2. In vitro, Rb4 induced F-actin polymerization, prevented F-actin depolymerization and increased the ER-derived cytosolic calcium. Such effects were associated with necrosis of murine melanoma B16F10-Nex2 cells and with inhibition of the viability of human cancer cell lines. Loss of plasma membrane integrity, dilation of mitochondria, cytoplasm vacuolation and absence of chromatin condensation characterized tumor cell necrosis. Cleavage of PARP-1 and inhibition of RIP1 expression were also observed. In vivo, peptide Rb4 reduced the lung metastasis of tumor cells and delayed the subcutaneous melanoma growth in a syngeneic model. Rb4 induced the expression of two DAMPs molecules, HMGB1 and calreticulin, in B16F10-Nex2. Our results suggest that peptide Rb4 acts directly on tumor cells inducing the expression of DAMPs, which trigger the immunoprotective effect in vivo against melanoma cells. We suggest that peptide Rb4 is a promising compound to be developed as an anticancer drug.
Collapse
Affiliation(s)
| | - Rodrigo Berzaghi
- Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil
| | - Denise C Arruda
- Integrated Group of Biotechnology, University of Mogi das Cruzes, UMC, Mogi das Cruzes, SP, Brazil
| | - Fabrício C Machado
- Recepta Biopharma, São Paulo, Brazil.,Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil
| | - Leticia L Loureiro
- Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil
| | - Pollyana M S Melo
- Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil
| | | | - Alexandre Budu
- Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil
| | - Luiz R Travassos
- Recepta Biopharma, São Paulo, Brazil.,Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil
| |
Collapse
|
4
|
Ghosh D, Dutta A, Kashyap A, Upmanyu N, Datta S. PLP2 drives collective cell migration via ZO-1-mediated cytoskeletal remodeling at the leading edge in human colorectal cancer cells. J Cell Sci 2021; 134:271878. [PMID: 34409455 DOI: 10.1242/jcs.253468] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Accepted: 08/11/2021] [Indexed: 01/06/2023] Open
Abstract
Collective cell migration (CCM), in which cell-cell integrity remains preserved during movement, plays an important role in the progression of cancer. However, studies describing CCM in cancer progression are majorly focused on the effects of extracellular tissue components on moving cell plasticity. The molecular and cellular mechanisms of CCM during cancer progression remain poorly explored. Here, we report that proteolipid protein 2 (PLP2), a colonic epithelium-enriched transmembrane protein, plays a vital role in the CCM of invasive human colorectal cancer (CRC) epithelium by modulating leading-edge cell dynamics in 2D. The extracellular pool of PLP2, secreted via exosomes, was also found to contribute to the event. During CCM, the protein was found to exist in association with ZO-1 (also known as TJP1) and to be involved in the positioning of the latter at the migrating edge. PLP2-mediated positioning of ZO-1 at the leading edge further alters actin cytoskeletal organization that involves Rac1 activation. Taken together, our findings demonstrate that PLP2, via its association with ZO-1, drives CCM in CRC epithelium by modulating the leading-edge actin cytoskeleton, thereby opening up new avenues of cancer research. This article has an associated First Person interview with the first author of the paper.
Collapse
Affiliation(s)
- Dipanjana Ghosh
- Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal 462066, India.,School of Pharmacy and Research, People's University, Bhopal 462037, India
| | - Ankita Dutta
- Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal 462066, India
| | - Anjali Kashyap
- Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal 462066, India
| | - Neeraj Upmanyu
- School of Pharmacy and Research, People's University, Bhopal 462037, India
| | - Sunando Datta
- Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal 462066, India
| |
Collapse
|
5
|
Lotesto MJ, Wallace CJ, Raimondi SL. E-Cadherin, NFATC3, and PLP2 Are Differentially Methylated in Multiple Cancers. Epigenet Insights 2020; 13:2516865720964802. [PMID: 33178991 PMCID: PMC7592331 DOI: 10.1177/2516865720964802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 09/14/2020] [Indexed: 11/30/2022] Open
Abstract
It is well documented that cancer cells have abnormal methylation patterns often caused by faulty methylating machinery. Specifically, E-cadherin, NFATC3, and PLP2 are 3 genes known to be aberrantly methylated in cancer cells. These genes are well documented for their role in signaling pathways involved with cell proliferation, adhesion, migration, and other signs of tumor progression. Therefore, changes in gene expression of CDH1, NFATC3, and PLP2 due to aberrant methylation can lead to profound changes in cellular function and tumor formation. In order to ensure that previous in vitro and in vivo methylation studies match what is observed in the clinic, we utilized a bioinformatics approach to complete an extensive analysis of methylation patterns of these 3 genes, analyzing over 5000 patient samples, across all cancers for which both normal and tumor tissues were available. Specifically, we analyzed overall and site-specific methylation patterns, at CpG islands and shores, of all 3 genes across 14 cancer types. Furthermore, we compared these methylation levels in normal and tumor samples of both matched and unmatched patient samples in order to determine any differences between groups. Finally, we examined whether an aberrant DNA methyltransferase, DNMT3B7, known to be expressed in cancer cells and to alter methylation patterns in vitro correlated with altered overall and site-specific methylation of CDH1, NFATC3, and PLP2 in these patient samples. Our results indicate that methylation patterns of CDH1 and NFATC3 were unexpectedly varied across tumors, contrary to previous studies performed in vitro, while PLP2 showed the expected hypomethylation pattern in tumor tissues. We also observed some correlation between DNMT3B7 expression and methylation patterns of these genes, but patterns were inconsistent. Taken together, these results emphasize the necessity for in vivo and patient studies rather than a complete reliance on in vitro data and provide multiple areas of future research.
Collapse
Affiliation(s)
- Mary J Lotesto
- Department of Biology, Elmhurst University, Elmhurst, IL, USA
| | | | | |
Collapse
|
6
|
Feng Z, Zhou W, Wang J, Qi Q, Han M, Kong Y, Hu Y, Zhang Y, Chen A, Huang B, Chen A, Zhang D, Li W, Zhang Q, Bjerkvig R, Wang J, Thorsen F, Li X. Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma. J Cell Mol Med 2019; 24:2847-2856. [PMID: 31778016 PMCID: PMC7077595 DOI: 10.1111/jcmm.14840] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 09/23/2019] [Accepted: 10/26/2019] [Indexed: 01/07/2023] Open
Abstract
Proteolipid protein 2 (PLP2) is an integral ion channel membrane protein of the endoplasmic reticulum. The protein has been shown to be highly expressed in many cancer types, but its importance in glioma progression is poorly understood. Using publicly available datasets (Rembrandt, TCGA and CGGA), we found that the expression of PLP2 was significantly higher in high‐grade gliomas than in low‐grade gliomas. We confirmed these results at the protein level through IHC staining of high‐grade (n = 56) and low‐grade glioma biopsies (n = 16). Kaplan‐Meier analysis demonstrated that increased PLP2 expression was associated with poorer patient survival. In functional experiments, siRNA and shRNA PLP2 knockdown induced ER stress and increased apoptosis and autophagy in U87 and U251 glioma cell lines. Inhibition of autophagy with chloroquine augmented apoptotic cell death in U87‐ and U251‐siPLP2 cells. Finally, intracranial xenografts derived from U87‐ and U251‐shPLP2 cells revealed that loss of PLP2 reduced glioma growth in vivo. Our results therefore indicate that increased PLP2 expression promotes GBM growth and that PLP2 represents a potential future therapeutic target.
Collapse
Affiliation(s)
- Zichao Feng
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China.,Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Wenjing Zhou
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China.,Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Jiwei Wang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China.,Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Qichao Qi
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Mingzhi Han
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Yang Kong
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Yaotian Hu
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China.,Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Yulin Zhang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Anbin Chen
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Bin Huang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Anjing Chen
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Di Zhang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Wenjie Li
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Qing Zhang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| | - Rolf Bjerkvig
- Department of Biomedicine, University of Bergen, Bergen, Norway.,Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Jian Wang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China.,Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Frits Thorsen
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China.,Department of Biomedicine, University of Bergen, Bergen, Norway.,The Molecular Imaging Center, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Xingang Li
- Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong Key Laboratory of Brain Functional Remodeling and Brain Science Research Institute, Shandong University, Shandong, China
| |
Collapse
|
7
|
LI Y, TANG J, HU Y, PENG Y, WANG J. Expression of miR-664-3p in Osteosarcoma and Its Effects on the Proliferation and Apoptosis of Osteosarcoma Cells. IRANIAN JOURNAL OF PUBLIC HEALTH 2019; 48:1817-1826. [PMID: 31850259 PMCID: PMC6908901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND To explore the expression level of miR-664-3p in osteosarcoma and its effects on the proliferation and apoptosis of osteosarcoma cells. METHODS Specimens of osteosarcoma tissues were collected from 41 cases undergoing surgical treatment in the Orthopedics Department of Wuhan Puai Hospital, Wuhan, China from January 2015 to February 2018. Another 40 cases of normal bone tissue were collected. The expression of miR-664-3p were detected using quantificational real-time polymerase chain reaction. miR-664-3p mimics, miR-664-3p inhibitor and miR-664-3p negative control (NC) were used to transfect U2-OS, which were named as mimics group, inhibitor group and NC group, respectively. MTT assay was adopted to detect the effects of microRNA-664-3p on the proliferation of U2-OS after 24, 48, 72, 96 and 120 hours of transfection. Flow cytometry was applied to measure the apoptosis rate of U2-OS after miR-664-3p transfection. Finally, Western Blot was employed to detect the expression of proteolipid protein 2 (PLP2). RESULTS The total apoptosis rate of cells in the inhibitor group was obviously higher than those in the mimics group and the NC group (P<0.001). The relative expression level of PLP2 in the inhibitor group was significantly lower than those in the mimics group and the NC group (P<0.001). CONCLUSION MiR-664-3p may be involved in the occurrence and development of osteosarcoma, and can regulate the proliferation and apoptosis of U2-OS cells, and the expression of PLP2. Besides, miR-664-3p may become a novel molecular biological indicator for the diagnosis, targeted treatment and prognosis assessment of osteosarcoma.
Collapse
Affiliation(s)
- Ye LI
- Department 3 of Orthopedics, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science, Wuhan 430034, P.R. China
| | - Jie TANG
- Department 3 of Orthopedics, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science, Wuhan 430034, P.R. China,Corresponding Author:
| | - Yong HU
- Department 3 of Orthopedics, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science, Wuhan 430034, P.R. China
| | - Yonghai PENG
- Department 3 of Orthopedics, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science, Wuhan 430034, P.R. China
| | - Junwen WANG
- Department 2 of Orthopedics, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science, Wuhan 430034, P.R. China
| |
Collapse
|
8
|
Zou Y, Chen Y, Yao S, Deng G, Liu D, Yuan X, Liu S, Rao J, Xiong H, Yuan X, Yu S, Zhu F, Wang Y, Xiong H. MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther 2018; 19:436-444. [PMID: 29509055 DOI: 10.1080/15384047.2018.1433497] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
OBJECTIVE This study investigated miR-422a and PLP2 expressions in breast cancer cells and breast cancer stem cells (BCSCs). Besides, their influences on polymorphism changes were observed. METHODS Flow cytometry and fluorescence-activated cell sorting was performed and CD24-/CD44+ cells were sorted from breast cancer cells and recognized as BCSCs. Microarray was applied to search for the differentially expressed miRNAs and mRNAs between MCF7 and BCSCs. The aberrant expression of miR-422a and PLP2 was further confirmed by RT-qPCR and the direct targeted relationship was verified by dual-luciferase reporter assay. After in vitro transfection, the expression of miR-422a and PLP2 were manipulated and biological functions of BMSCs were compared with CCK-8, colony formation and sphere formation assay. The tumorigenesis ability of transfected BMSCs was also investigated in NOD/SCID tumor mice models. RESULTS BMSCs were successfully established from MCF7 cells and miR-422a expression was downregulated while PLP2 level decreased in BMSCs. MiR-422a directly targets the 3'UTR of PLP2 and suppressed its expression. Besides, the up-regulation of miR-422a contributed to weakened ability of proliferation and microsphere formation of BMSCs, while PLP2 overexpression facilitated those biological abilities. Tumorigenesis of BMSCs in mice models was impaired by either overexpression of miR-442a or silencing of PLP2. CONCLUSION Up-regulation of miR-422a attenuated microsphere formation, proliferation and tumor formation of breast cancer stem cells via suppressing the PLP2 expression.
Collapse
Affiliation(s)
- Yanmei Zou
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Yuandong Chen
- b Department of Oncology , Huangzhou District People's Hospital , Huanggang , Hubei , China
| | - Shuo Yao
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Guangrui Deng
- b Department of Oncology , Huangzhou District People's Hospital , Huanggang , Hubei , China
| | - Dian Liu
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Xun Yuan
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Shunfang Liu
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Jie Rao
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Huihua Xiong
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Xianglin Yuan
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Shiying Yu
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Feng Zhu
- d Department of Biochemistry and Molecular Biology , School of Basic Medicine, Huazhong University of Science and Technology , Wuhan , Hubei , China
| | - Yihua Wang
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China.,c Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton , Southampton , UK
| | - Hua Xiong
- a Department of Oncology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , Hubei , China
| |
Collapse
|
9
|
Calloni R, Bonatto D. Scaffolds for Artificial miRNA Expression in Animal Cells. Hum Gene Ther Methods 2015; 26:162-74. [PMID: 26406928 DOI: 10.1089/hgtb.2015.043] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Artificial miRNAs (amiRNAs) are molecules that have been developed to promote gene silencing in a similar manner to naturally occurring miRNAs. amiRNAs are generally constructed by replacing the mature miRNA sequence in the pre-miRNA stem-loop with a sequence targeting a gene of interest. These molecules offer an interesting alternative to silencing approaches that are based on shRNAs and siRNAs because they present the same efficiency as these options and are less cytotoxic. amiRNAs have mostly been applied to gene knockdown in plants; they have been examined to a lesser extent in animal cells. Therefore, this article reviews the amiRNAs that have been developed for animal cells and focuses on the miRNA scaffolds that can already be applied to construct the artificial counterparts, as well as on the different approaches that have been described to promote amiRNA expression and silencing efficiency. Furthermore, the availability of amiRNA libraries and other tools that can be used to design and construct these molecules is briefly discussed, along with an overview of the therapeutic applications for which amiRNAs have already been evaluated.
Collapse
Affiliation(s)
- Raquel Calloni
- Centro de Biotecnologia da Universidade Federal do Rio Grande do Sul, and Departamento de Biologia Molecular e Biotecnologia, Universidade Federal do Rio Grande do Sul , Porto Alegre, Brazil
| | - Diego Bonatto
- Centro de Biotecnologia da Universidade Federal do Rio Grande do Sul, and Departamento de Biologia Molecular e Biotecnologia, Universidade Federal do Rio Grande do Sul , Porto Alegre, Brazil
| |
Collapse
|
10
|
Ding Z, Jian S, Peng X, Liu Y, Wang J, Zheng L, Ou C, Wang Y, Zeng W, Zhou M. Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2. Medicine (Baltimore) 2015; 94:e1327. [PMID: 26287415 PMCID: PMC4616445 DOI: 10.1097/md.0000000000001327] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2015] [Revised: 07/14/2015] [Accepted: 07/15/2015] [Indexed: 11/26/2022] Open
Abstract
Proteolipid protein 2 (PLP2) has been shown to be upregulated in several cancers, including breast cancer, hepatocellular carcinoma, osteosarcoma, and melanoma. PLP2 specifically binds to phosphatidylinositol 3 kinase to activate the protein kinase B pathway to enhance cell proliferation, adhesion, and invasion in melanoma cells. Therefore, we speculated that PLP2 exhibits oncogenic potential. However, the regulatory mechanisms of PLP2 in cancer cells remain unclear.Herein, we found that microRNA (miR)-664 expression was significantly downregulated in cutaneous malignant melanoma (CMM) cells and tissues compared with normal human melanocytes and benign melanocytic naevi. MiR-664 expression level was significantly correlated with patient survival. Ectopic expression of miR-664 reduced CMM cell proliferation and anchorage-independent growth, whereas the inhibition of miR-664 induced these effects. Furthermore, inhibition of miR-664 in CMM cells resulted in modulation of their entry into the G1/S transitional phase, which was caused by downregulation of the cyclin-dependent kinase inhibitor P21 and upregulation of the cell-cycle regulator cyclin D1. Moreover, we demonstrated that miR-664 downregulated PLP2 expression by directly targeting the PLP2 untranslated region.Taken together, our results suggest that miR-664 may play an important role in suppressing proliferation of CMM cells and present a novel mechanism of miR-mediated direct suppression of PLP2 expression in cancer cells.
Collapse
Affiliation(s)
- Zhenhua Ding
- From the Department of Radiation Medicine (ZD, LZ, CO, YW, MZ), School of Public Health and Tropic Medicine, Southern Medical University,Guangzhou,Guangdong,China; Department of Hepatobiliopancreatic Surgery (SJ), Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou,Guangdong,China Department of Dermatology (XP), Nanfang Hospital, Southern Medical University,Guangzhou,Guangdong,China; Guangzhou Twelfth Hospital (YL, JW); and Guangzhou Biocare Cancer Institute (WZ), Guangzhou, Guangdong, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kasahara T. [Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity]. YAKUGAKU ZASSHI 2015; 135:431-47. [PMID: 25759052 DOI: 10.1248/yakushi.14-00237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
I have been engaged in research and education in the fields of immunology and biochemistry at a medical college and college of pharmacy for 40 years. The original reasons why I began studying cytokines and some of the interests that have motivated me to continue working in the field of cytokine research are described: 1) the roles of cytokines in various immunological and inflammatory diseases (e.g., chemokines in bacterial infections and inflammatory diseases, particularly the role of interleukin-5 and eotaxins in eosinophilia); 2) the role of focal adhesion kinase in antiapoptosis and metastasis of melanoma; 3) recent findings on the role of JAK2/STAT pathways, particularly how JAK2V617F mutation induces dysregulated proliferation and tumorigenesis; and 4) the interactions of various chemical compounds and natural products in cytokine gene activation and signaling. Previous discoveries and published findings by my research group are described, along with comments and discussion pertaining to recent developments in the field.
Collapse
Affiliation(s)
- Tadashi Kasahara
- Graduate School, International University of Health and Welfare; 1-3-3 Minamiaoyama, Minato-ku, Tokyo 107-0062, Japan; Keio University Faculty of Pharmacy; 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan; Division of Inflammation Research, Jichi Medical University; 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
| |
Collapse
|